AbZelectPRO™: Enhanced Cell Line Development - Abzena

Is your cell line development (CLD) strategy GMP-ready from day one? Discover AbZelectPRO™

Achieve stable pools in 3 weeks and accelerate from DNA to RCB in just 10 weeks & GMP in 6 months with our industry-leading mammalian cell line development services. Discover AbZelectPRO™. Fully portable. No Abzena exit fees. No royalties. Single milestone payment at IND*.

Get Started What is AbZelectPRO™?
Full Services Page

Achieve More With Our Enhanced CLD Platform: AbZelectPRO™

Fully Integrated Stable Pools to GMP Solution

CLD Services - Proven Performance - Abzena

Proven
Performance

High-quality mAb titers up to 10 g/L, sustained over 60 generations

CLD Services - Reduced Timelines - Abzena

Reduced
Timelines

Stable Pools in 3 weeks, RCB in 10 weeks, GMP in 6 Months

CLD Services - High Quality - Abzena

High
Quality

PQA integrated into all stages,​ full traceability & compliant with ICH-Q5

CLD Services - Ensured Scalability - Abzena

Ensured
Scalability

Engineered for scalability with robust bioreactor performance from the very start

Leverage an established, high-performance cell line platform, AbZelectPRO™, designed to deliver scalable titers, consistent PQAs, and seamless transition into GMP manufacturing.

 

Contact Our CLD Experts

It is never too early to research your mammalian cell line development (CLD) options. Opportunity is right here. Who can you count on for rapid and high yielding cell line development service? Abzena. We partnered with industry leading firms, Revvity and ProteoNic Biosciences, to offer you the most robust, GMP-ready, stable cell line development platform. Abzena offers fully integrated stable pools to GMP manufacturing solutions with AbZelectPRO™.

Abzena are as committed to the downstream success and quality of your drug as you are. We have the expertise, partnerships, and capacity to move your mammalian cell line development program forward.

Standalone and integrated CLD models available with transparent pricing to IND with no royalty fees & no exit fees.

Revvity’s CHOSOURCE™ Glutamine Synthetase (GS) knockout cell line is a well-established, cGMP-manufactured CHO-K1-derived suspension cell line.

ProteoNic’s 2G UNic® vector boosts CHO cell protein yields by enhancing transcription, translation, and stability – enabling high titers and rapid cell line development.

* A Strategic Partner Fee is applicable if/when license holder transfers asset to another party.

What is AbZelectPRO™?

AbZelect™ & AbZelectPRO™: Enhanced Cell Line Development - Abzena


AbZelectPRO™ streamlines stable cell line development, enhances efficiency, and cuts timelines to IND application. Tailored for small to midsize biotechnology companies with antibody-based therapeutics, AbZelectPRO™ has been designed to accommodate diverse modalities and is supported by our strong analytical expertise.

AbZelectPRO™ Platform Overview

– Cell Lines: CHO-K1, CHOSOURCE™, CHOSOURCE™ ADCC+
– GMO : None, CHO-K1 GS -/-, GS & Fut 8
– Vector: 2G UNic®
– Fee(s): License fee at IND
– Media: Off-the-shelf commercial media and feeds that are chemically defined & animal component-free
– ProteoNic’s 2G UNic® increases CHO productivity through enhanced transcription, translation, and stability—enabling rapid CLD
– Revvity’s CHOSOURCE™ GS‑knockout is a cGMP‑manufactured, CHO‑K1 suspension cell line with a strong development track record
– CHOSOURCE™ ADCC+ is a dual GS and fucosyltransferase knockout, enabling production of afucosylated proteins

*Strategic Partner fee applicable if/when the license holder transfers the asset to another party.

Download our Info Sheet now to discover more and contact us.

Download Our CLD Info Sheet Contact Us

The Abzena Advantage: One Partner. Less Time in Development. Less Risk.

We remove the gaps, dependencies & delays that slow your program from cell line to GMP.

CLD Services - Scale Confidently from Bench to GMP

Scale Confidently from Bench to GMP

  • Consistent, high-titer material at 50L, 500L and 2,000L — no performance cliffs
  • Minimal upstream process development (PD)
  • High-quality stable pools & clones that perform the same at every scale
CLD Services - Faster to Drug Substance

Faster to Drug Substance

  • Stable pool material enables downstream, analytical & formulation work to start immediately
  • Fewer upstream PD cycles compresses your timeline to IND-enabling studies
  • Tox material provision decoupled from final cell line selection
CLD Services - De-Risk Your Critical Path

De-Risk Your Critical Path

  • Analytical, formulation, & downstream PD run in parallel with CLD to reduce bottlenecks
  • Stable, predictable material reduces late-stage reformulation & process failures
  • One integrated partner removes handoff risk & keeps momentum

Compress Your Timeline. Eliminate the White Space.

Ask Abzena's experts that understand your challenges.

Ask Abzena: John Gill, VP & Scientific Leader of Cell Line Development

John Gill, VP & Scientific Leader of Cell Line Development - Abzena

Is your cell line development strategy GMP-ready from day one?

The decision of where to develop your cell line has more downstream consequences than it might first appear. For CMC teams, splitting cell line development (CLD) & GMP manufacturing across multiple organizations is one of the most common sources of program risk. This can fragment process knowledge, introduce tech transfer delays, and create analytical gaps that are costly to resolve later. Keeping everything under one roof means the team selecting your clones is the same team scaling them up. Process and analytical decisions are made with GMP in mind from the start, and continuity is built in rather than bolted on.

Have a question about your CLD strategy or how an integrated CLD-to-GMP approach could work for your program? Ask our expert – John Gill, VP & Scientific Leader of Cell Line Development. John has spent his career helping CMC teams with these decisions – from clone selection and platform fit through to GMP readiness. Whether you’re early in early development or rethinking your current approach, John is ready to have that conversation.

Contact Our Expert About John Gill

CLD Strategies that Reduce Timelines & Costs

Gain actionable insights into integrating innovative CLD technologies, de-risking strategies, and efficient development approaches to maximize the success of your biologics program.

Watch Abzena’s Brett Verstak, Director of Cell Line Development excerpt on AbZelectPRO™ and request full access to the on-demand webinar recording by clicking the button below.

Watch Recording

What sets Abzena apart?

Access to Genuine Scientific & Technical Experts

We have over 20 years of experience in delivering solutions at each stage of the development lifecycle from early-stage research and discovery, through lead candidate selection, and onward into process development and GMP manufacture.

Unlike most other service providers, we can provide technical and scientific support that truly spans early-stage research through process development and GMP manufacturing under a single organization to better ensure that the TPP can be achieved. Our global scientific teams have extensive experience in overcoming some of the most challenging and complex biologic and bioconjugate programs, making us the perfect partner for novel and disruptive technologies that other biopharmaceutical CDMOs may shy away from.

Discover Our History

Proactive Problem Solving to Ensure Downstream Success

Our experienced team is focused on getting it right from the start. We identify and address challenges early in drug design to better ensure downstream clinical and commercial success. We also have expertise in fixing and optimizing drugs in later stage development to rescue them from the drug development graveyard.

Discover Developability

Diverse & Interconnected Expertise Under a Single Organization

With capabilities ranging from bioassays to cell line development, bioconjugation and clinical and commercial manufacturing, all under one organization, we can reduce the white space in the development path, which ultimately minimizes risk, reduces costs and accelerates timelines for our customers.

As an integrated service provider, we accelerate timelines through the ease of technical and materials transfer, and improved scheduling. Better workflows and processes can also be attained through improved knowledge transfer between internal multidisciplinary experts and the development of a deep understanding of the drug as it progresses from target to lead selection and process development and manufacture.

Biologic Services

Driven by Innovation to Streamline Development

Our team is always seeking new ways to innovate and streamline development for our customers. Our extensive scientific capabilities and proprietary solutions like EpiScreen® 2.0, Composite Proteins™, Composite Human Antibodies™, AbZelectPRO™, ThioBridge™, and LabZient™ are designed to give your program the best chance of clinical and commercial success.

  • EpiScreen® 2.0 — an extensive suite of bioinformatic and primary human cell-based assays for immunogenicity assessment to inform of potential safety and efficacy risks in the clinic.
  • Composite Human Antibody™ — a platform used for designing safer, more effective, humanized antibodies.
  • Composite Proteins™ — a deimmunization technology that designs safer and more effective therapeutic proteins, devoid of human T cell epitopes, to minimize potential immunogenicity in patients without compromising activity.
  • AbZelectPRO™ — high-yielding cell line development (CLD) platform for accelerating the generation of production cell lines for manufacture of antibodies and recombinant proteins.
  • ThioBridge™ — a next-generation conjugation linker technology proven to enhance ADC development by overcoming issues with existing technologies to improve stability, potency, and efficacy.
  • LabZient™ — our analytical platform that combines predictive in-silico evaluation with laboratory methods to de-risk the application of platform analytical procedures and expedites the pathway to IND.
Discover Our Solutions

A history of successfully moving medicine forward

20+

years of complex biologics and bioconjugation services experience

2000+

conjugates developed for critical assays, and lead candidate selections with over 400 ADCs produced

50+

bioconjugation programs scaled up to produce multi gram batches

 

Each CLD program has a dedicated team, ensuring consistency and expertise transfer to our manufacturing facilities. Move forward from DNA to RCB in 10 weeks with 10g/L in high-performing titers and de-risk the path to IND with Abzena’s enhanced AbZelectPRO™ cell line development platform today.


For reliable, stable CHO cell line development, start a conversation with our scientific experts at Abzena today.